<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449175</url>
  </required_header>
  <id_info>
    <org_study_id>03-C11-001PLV</org_study_id>
    <nct_id>NCT01449175</nct_id>
  </id_info>
  <brief_title>A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema</brief_title>
  <official_title>A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long
      term safety and efficacy information about the AeriSeal System treatment in patients with
      advanced emphysema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long
      term safety and efficacy information about the AeriSeal System treatment in patients with
      advanced homogeneous or heterogeneous emphysema.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of Serious Adverse Events (SAE)</measure>
    <time_frame>Weeks 48, 96, 120, 144 following treatment</time_frame>
    <description>Count number of SAEs during weeks: 48, 96, 120, 144 as a function of long term safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vital Signs</measure>
    <time_frame>weeks 48, 96, 120, 144 following treatment</time_frame>
    <description>Change from baseline at 48, 96, 120 and 144 weeks of Vital Signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxygen (O2) Use</measure>
    <time_frame>Weeks 48, 96, 120, 144 following treatment</time_frame>
    <description>Change in amount of O2 used (at rest, with activity, during sleep) in weeks 48, 96, 120 and 144 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in medications</measure>
    <time_frame>week 48, 96, 120, 144 following treatment</time_frame>
    <description>Change in medication regiment in weeks 48, 96, 120 and 144 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Function Tests (PFT)</measure>
    <time_frame>Weeks 48, 96, 120, 144 following treatment</time_frame>
    <description>Change in PFT (Spirometry, Diffusing Capacity, Plethysmograpy) in weeks 48, 96, 120 and 144 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in notable radiology results</measure>
    <time_frame>weeks 48, 96, 120, 144 following treatment</time_frame>
    <description>Change in notable radiology results (infiltrates, mass lesions, pleural abnormalities) from baseline in weeks 48, 96, 120 and 144.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Chronic Pulmonary Obstructive Disease</condition>
  <condition>Emphysema</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients participating in the Registry Study must have been enrolled in either Group 4
        (homogeneous emphysema) or Group 5 (heterogeneous emphysema) of Aeris' Investigational
        Study 03-C08-003PLV and completed 48 week follow-up in the AeriSeal post market follow-up
        Continuation Study (03-C10-001PLV).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of completion of Aeris' post market follow-up Continuation Study,
             03-C10-001PLV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Otto Wagner Spital Wien</name>
      <address>
        <city>Wein</city>
        <zip>A-1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital Pasteur, Centre Hospitalier Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002 Cedex 1</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>D-99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LungenKlinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>D-58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Medizinische Klinik und Poliklinik Klinikum Großhadern</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheeva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AeriSeal</keyword>
  <keyword>treatment</keyword>
  <keyword>device</keyword>
  <keyword>breathing</keyword>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>polymeric lung volume reduction (PLVR)</keyword>
  <keyword>biologic lung volume reduction (BLVR)</keyword>
  <keyword>heterogeneous</keyword>
  <keyword>homogeneous</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Pulmonary Disease, Chronic Obstructive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

